Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for oncology and complement-related conditions. Its pipeline includes NXP900, an oral small molecule inhibitor of SRC and YES1 kinases, currently in Phase 1b trials for advanced solid tumors such as breast, colon, prostate, and lung cancers. NXP900 is being evaluated as a single agent and in combination with EGFR and ALK inhibitors. The company also develops NXP100, a complement Factor B inhibitor for diseases caused by dysregulated complement activity, and NXP200, a paradox breaker BRAF inhibitor for advanced cancers. NXP800, a GCN2 kinase activator, is under evaluation for platinum-resistant ovarian cancer and cholangiocarcinoma. Nuvectis Pharma was formerly known as Centry Pharma, Inc. and was founded in 2020. The company holds worldwide commercial rights to NXP900, licensed from the University of Edinburgh.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage nuvectis.com
Sector Healthcare IR page nuvectis.com/investors
Tags
oncology, precision medicine, kinase inhibitors, complement inhibitors, solid tumors, src kinase, yes1 kinase, braf inhibitor, clinical-stage, small molecule, NXP900, NXP100, NXP200, NXP800, Centry Pharma Inc.
Press page —

Metrics

Valuation  
Market cap $ 726.294M
Market cap (USD) $ 726.294M
P/E -11.17
PEG —
P/BV 5.73
P/S —
P/OCF -18.02
P/FCF -45.37
Dividend yield —
Turnover / mcap —
Returns  
ROE -188.0%
ROI -143.6%
ROIC -112.3%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 5
Quality score -83.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Assets 31.709M 18.607M 19.185M 20.405M 6.657M
Net profit -26.442M -19M -22.26M -19.085M -12.89M
Free cash flow -16.009M -12.247M -15.954M -13.559M -9.504M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 7.55 5.41 8.34 7.5 —
Price performance 12m 0.4 -0.35 0.11 — —

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Cash and deposits (USD) 5.74M 20M 19.1M 18.5M 31.6M
Cash flow detail
Operating cash flow (USD) -9.5M -13.6M -16M -12.2M -16M
Change in payables (cash effect) (USD) 1.59M 4.14M -139,000 -273,000 3.78M
Share-based compensation (USD) 1.89M 1.71M 4.71M 4.86M 6.03M
Income detail
Research and development expense (USD) 9.55M 13.2M 15.4M 12.9M 18.2M
Reported Mar 8, 2023 Mar 8, 2023 Mar 5, 2024 Feb 25, 2025 Feb 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 4, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report.

Skip To Main Content

This website is AudioEye enabled and is being optimized for accessibility. To open the AudioEye Toolbar, press "shift + =". Some assistive technologies may require the use of a passthrough function before this keystroke. For more information, activate the button labeled "Explore your accessibility options".

Revisit consent button

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... Show more

NecessaryAlways Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Uncategorized

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Reject All Save My Preferences Accept All

Powered by

Nuvectis Pharma

Precision Medicine for the Treatment of Complement Related Diseases and Cancer

Explore our pipelineInvestor Relations

Innovative precision medicine for the treatment of complement-related conditions and oncology

Nuvectis Pharma (Nasdaq: NVCT) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. Our lead candidate is ciprocopan, a Factor B inhibitor for once daily oral administrations, with best-in-class potential, approved in China in July 2026 for treatment of PNH in patients previously untreated with complement inhibitors. Our oncology pipeline includes NXP200 (paradox breaking, BRAF kinase inhibitor) and NXP900 (YES1/SRC kinase inhibitor) for the treatment of advanced cancers.

PipelineOur complement and oncology programs, from mechanism to clinic.Learn moreLeadershipMeet the management team and board of directors.Learn moreInvestor RelationsStock information, filings, events and presentations.Learn more

Pipeline

Our programs

ComplementNXP100Complement Factor B InhibitorNXP100 is a small molecule for oral, once daily administration that inhibits Factor B, a critical protease within the alternative pathway of the complement cascade.View programOncologyNXP200Paradox Breaker BRAF InhibitorNXP200 is an oral small-molecule, paradox breaker BRAF inhibitor.View programOncologyNXP900SRC/YES1 Kinase InhibitorNXP900 is an oral small-molecule inhibitor targeting the SRC Family of Kinases (SFKs), with low nanomolar potency for SRC and YES1.View program

Explore our pipeline

News

Latest Press Releases

View all press releases

November 4, 2026Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business HighlightsRead moreNovember 2, 2026Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026Read moreOctober 26, 2026Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive GliomasRead moreOctober 9, 2026Nuvectis Pharma to Participate in the Maxim Growth Summit 2026Read moreSeptember 24, 2026Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade GliomaRead moreSeptember 3, 2026Nuvectis Pharma To Participate in Upcoming Investor ConferencesRead moreAugust 4, 2026Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business HighlightsRead moreJuly 23, 2026Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement InhibitorsRead more

Email Alerts

Stay informed

Get Nuvectis press releases and SEC filings delivered to your inbox.

Opens in new window

PDF Download

Word Download

Excel Download

PowerPoint Download

Document Download

Explore your accessibility options

Skip To Main Content

This website is AudioEye enabled and is being optimized for accessibility. To open the AudioEye Toolbar, press "shift + =". Some assistive technologies may require the use of a passthrough function before this keystroke. For more information, activate the button labeled "Explore your accessibility options".

Revisit consent button

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... Show more

NecessaryAlways Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Uncategorized

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Reject All Save My Preferences Accept All

Powered by

Nuvectis Pharma

Precision Medicine for the Treatment of Complement Related Diseases and Cancer

Explore our pipelineInvestor Relations

Innovative precision medicine for the treatment of complement-related conditions and oncology

Nuvectis Pharma (Nasdaq: NVCT) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. Our lead candidate is ciprocopan, a Factor B inhibitor for once daily oral administrations, with best-in-class potential, approved in China in July 2026 for treatment of PNH in patients previously untreated with complement inhibitors. Our oncology pipeline includes NXP200 (paradox breaking, BRAF kinase inhibitor) and NXP900 (YES1/SRC kinase inhibitor) for the treatment of advanced cancers.

PipelineOur complement and oncology programs, from mechanism to clinic.Learn moreLeadershipMeet the management team and board of directors.Learn moreInvestor RelationsStock information, filings, events and presentations.Learn more

Pipeline

Our programs

ComplementNXP100Complement Factor B InhibitorNXP100 is a small molecule for oral, once daily administration that inhibits Factor B, a critical protease within the alternative pathway of the complement cascade.View programOncologyNXP200Paradox Breaker BRAF InhibitorNXP200 is an oral small-molecule, paradox breaker BRAF inhibitor.View programOncologyNXP900SRC/YES1 Kinase InhibitorNXP900 is an oral small-molecule inhibitor targeting the SRC Family of Kinases (SFKs), with low nanomolar potency for SRC and YES1.View program

Explore our pipeline

News

Latest Press Releases

View all press releases

November 4, 2026Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business HighlightsRead moreNovember 2, 2026Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026Read moreOctober 26, 2026Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive GliomasRead moreOctober 9, 2026Nuvectis Pharma to Participate in the Maxim Growth Summit 2026Read moreSeptember 24, 2026Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade GliomaRead moreSeptember 3, 2026Nuvectis Pharma To Participate in Upcoming Investor ConferencesRead moreAugust 4, 2026Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business HighlightsRead moreJuly 23, 2026Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement InhibitorsRead more

Email Alerts

Stay informed

Get Nuvectis press releases and SEC filings delivered to your inbox.

Opens in new window

PDF Download

Word Download

Excel Download

PowerPoint Download

Document Download

Explore your accessibility options

Prompts

Nuvectis Pharma, Inc. (ticker NVCT), listed in United States.

ETFs Holding Nuvectis Pharma, Inc.

ETF Weight in ETF Shares Market value As of
FSEG 0.07% 207 $ 3,806.73 Jun 30, 2026